Original Article

The effectiveness of tamsulosin hydrochloride with terazosin combination therapy for chronic prostatitis Type-III b

*Bin Duan*, **Xinxi Wang**

**ABSTRACT**

**Objectives:** To study the therapeutic effects of combined tamsulosin hydrochloride and terazosin treatment for patients with chronic prostatitis Type-III b.

**Methods:** This study involved 180 patients with chronic prostatitis Type-III b treated between January 2018 and December 2020 conducted at Nanhua Hospital Affiliated to Nanhua University. Patients were randomly divided into two equal groups: one receiving oral terazosin hydrochloride tablets only (control group), and one orally receiving both tamsulosin hydrochloride sustained-release tablets and terazosin hydrochloride tablets (observation group). Outcome measurements included symptom scoring, inflammatory cytokine levels, as well as white blood cell and lecithin body counts in the prostatic fluid.

**Results:** After 30 days of treatment, the observation group showed greater treatment effectiveness (86.67% vs. 73.33%, P<0.05). QLS, US5, PS, and NIH-CPSI symptom scores were lower in the observation group than the control group (P<0.05). No differences in adverse event distribution and incidence were noted. EPS IL-2 increased more in the observation group, while PGE-2, MIP-1α, and MIP-2 decreased more in the observation group. WBC levels decreased more in the observation group, while lecithin body levels increased more in the observation group.

**Conclusion:** The combination of tamsulosin hydrochloride and terazosin for the treatment of patients with chronic prostatitis Type-III b has a significant effect. This approach reduced patient symptoms, lowered inflammatory biomarkers, and generally improved quality of life. This approach appears to have clinical value worthy of future investigation.

**KEYWORDS:** Tamsulosin hydrochloride, Terazosin, Chronic prostatitis, Immune-mediated factor.

How to cite this:
Duan B, Wang X. The effectiveness of tamsulosin hydrochloride with terazosin combination therapy for chronic prostatitis Type-III b. Pak J Med Sci. 2022;38(3):595-599. doi: https://doi.org/10.12669/pjms.38.3.4931

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Chronic prostatitis (also known as Type-III clinical prostatitis), defined as a non-bacteria-related chronic inflammation of the prostate tissue, is caused by a variety of factors. Within the patient, chronic prostatitis is often accompanied by elevated prostatic secretions, inflammatory cells, prostate hyperplasias and other symptoms. Chronic prostatitis Type-III can be divided into Type-III a and III b, with the main symptoms for Type-III b being pain and irritation around the perineum, waist and back, lower abdomen, and urinary tract. In chronic disease, symptoms flare repeatedly, leading to a serious impact on patient quality of life. Alpha-blockers such as terazosin
are commonly used to treat chronic prostatitis, resulting in improved maximum flow rate as well as reduced dysuria and urodynia.\textsuperscript{3,4} While they are well tolerated, using a single drug for a long course of treatment can have unclear effects on drug efficacy.\textsuperscript{5} Tamsulosin blocks adrenoreceptors around the prostate, relaxes smooth muscle, relieves urethral spasm, and improves dysuria and urinary frequency.\textsuperscript{6} In this study, tamsulosin hydrochloride and terazosin were used to treat patients with chronic prostatitis Type-III b, and the clinical efficacy and the changes of immune mediators in prostatic fluid were investigated.

**METHODS**

The records of patients with chronic prostatitis Type-III b who came to our hospital for treatment from January 2018 to December 2020 were selected, there were 180 patients, including 118 males and 62 females.

**Inclusion Criteria:**
1. Patients diagnosed with chronic prostatitis Type-III b,\textsuperscript{7}
2. Course of disease exceeding 3 months,
3. Patient was between 18 and 65 years of age,
4. Patients presenting the following clinical symptoms-expressed prostatic secretions (EPS) (Obtained by a urologist through prostate massage) containing white blood cell (WBC) counts \( \leq 10/\text{HP} \), negative EPS cultures, and pelvic region pain.

**Exclusion criteria:**
1. Patients with drug addiction, alcoholism, drug abuse and mental illnesses,
2. Patients with cardiopulmonary diseases,
3. Patients with nervous system diseases, urinary system tumors, or urinary tract stenosis,
4. Patients treated with other drugs within the previous month
5. Patients with urinary system infections within the previous six months.

This study was approved by the medical research ethics committee of Nanhua Hospital Affiliated to Nanhua University (No.: 2021005; Date: April 18, 2021). The patients were randomly divided into observation and control groups of equal size. There was no significant difference in the basic characteristics between the two different treatment methods (\( P > 0.05 \)) (Table-I).

| Group                        | Sex (M/F) | Age (years) | Course of disease (m) |
|------------------------------|-----------|-------------|-----------------------|
| Control Group (n=90)         | 58/32     | 33.72±9.37  | 18.63±6.83            |
| Observation Group (n=90)     | 60/30     | 32.96±10.21 | 19.04±7.72            |

\( \chi^2/t \) 0.098 0.517 0.379 
\( P \) 0.754 0.606 0.705

Data were expressed as mean \( \pm \) SD; t-test was used for between-groups analysis. Chi-square test \( (\chi^2) \) was used when data were expressed as percentages. \( P < 0.05 \) indicated statistical significance.
pain score (PS, 0–21-point scale), for a maximum of 43 points. Patient score is directly proportional to symptom severity and inversely proportional to quality of life.

**Detection of Inflammatory Factors in EPS:** Macrophage inflammatory protein-2 (MIP-2), macrophage inflammatory protein-1β (MIP-1β), interleukin-2 (IL-2), and prostaglandin E2 (PGE-2) levels were detected by radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA) before and after treatment according to manufacturer’s instructions. To assess WBC counts, 20 μL of 6 U/mL heparin solution was mixed with 100 μL peripheral blood and add 10 μL filtered ink. The solution was incubated at 37°C for 4 hours, after which blood smears were prepared, dried, and stained with Wright’s stain. 100 mature neutrophils and immature neutrophils were counted under microscope, and 20 monocytes were counted too.

- Prostatic fluid was collected from patients and observed under microscopy for visual confirmation of lecithin body presence. Drug-related adverse reactions, including hypotension, nausea, headache, dizziness and others, were monitored.

**Data Analysis:** All data were analyzed using SPSS 18.0 software. Data were expressed as Mean ± SD, with t-tests used to examine differences between groups. Chi-square tests ($\chi^2$) were used when data were expressed as percentages. $P< 0.05$ indicated statistical significance.

**RESULTS**

After 30 days of treatment, the total effectiveness for the observation group was 86.67%, while the effectiveness in the control group was 73.33% (Table-II, $P < 0.05$). Prior to treatment, QLS, USS, PS, and NIH-CPSI symptom scores were similar among the control and observation groups. After treatment, while QLS, USS, PS, and NIH-CPSI symptom scores decreased in both groups, the decrease was greater in the observation group (Table-III, $P<0.05$).

### Table-II: Therapeutic effects of the two treatment strategies.

| Group            | n  | Ineffective | Effective | Remarkable effect | Cure | Effective rate % |
|------------------|----|-------------|-----------|-------------------|------|------------------|
| Control Group    | 90 | 24          | 44        | 16                | 6    | 73.33            |
| Observation Group| 90 | 12          | 50        | 20                | 8    | 86.67            |

$\chi^2$ = 6.065, $P=0.014$

Data were expressed as mean ± SD; t-test was used for between-groups analysis. Chi-square test ($\chi^2$) was used when data were expressed as percentages. $P< 0.05$ indicated statistical significance.

### Table-III: NIH-CPSI Symptom Scores Before and After Treatment.

| Group            | n  | Time          | QLS ± SD | USS ± SD | PS ± SD | NIH-CPSI ± SD |
|------------------|----|---------------|----------|----------|---------|---------------|
| Control Group    | 90 | Before treatment | 5.49±1.53 | 7.49±1.10 | 17.18±1.84 | 30.16±1.73 |
|                  |    | After treatment | 4.13±1.21 | 5.98±1.09 | 15.31±1.67 | 25.42±1.47 |
| Observation Group| 90 | Before treatment | 5.50±1.49 | 7.53±1.21 | 17.21±1.38 | 30.24±1.32 |
|                  |    | After treatment | 2.79±1.09 | 4.38±1.13 | 12.35±1.42 | 19.52±1.07 |

Data were expressed as mean ± SD; a: $P < 0.05$ compared against before treatment, b: $P < 0.05$ compared against control group; $P< 0.05$ indicated statistical significance.

### Table-IV: EPS IL-2 and PGE-2 levels before and after treatment.

| Group            | n  | Time          | MIP-1α (pg/ml) | MIP-2 (ng/ml) | IL-2 (ng/ml) | PGE-2 (ng/ml) |
|------------------|----|---------------|----------------|---------------|--------------|---------------|
| Control Group    | 90 | Before treatment | 39.21±5.28 | 96.47±5.93 | 1.89±0.58 | 870.37±38.62 |
|                  |    | After treatment | 33.25±6.34 | 85.28±6.03 | 2.29±0.63 | 561.28±28.93 |
| Observation Group| 90 | Before treatment | 39.19±4.82 | 95.97±4.29 | 1.92±0.62 | 880.73±40.72 |
|                  |    | After treatment | 26.89±5.28 | 63.74±6.29 | 2.84±0.66 | 330.31±30.62 |

Data were expressed as mean ± SD; a: $P < 0.05$ compared against before treatment, b: $P < 0.05$ compared against control group; $P< 0.05$ indicated statistical significance.
Prior to treatment, both groups presented similar EPS levels of IL-2 and PGE-2. After treatment, EPS IL-2 levels increased in both groups, while PGE-2, MIP-1α, and MIP-2 levels decreased in both groups. The IL-2 increase, as well as the PGE-2 and MIP-1α decreases, were greater in the observation group than the control group (Table-IV, P < 0.05).

WBC counts and lecithin body levels were similar between the two groups before treatment. After treatment, WBC levels decreased in both groups, while lecithin body counts increased in both groups. However, the magnitude of these changes was greater in the observation group (Table-V, P > 0.05).

Adverse reactions: No differences in adverse reactions were noted between patients in the two groups during and after treatment (Table-VI).

**DISCUSSION**

Terazosin, as an alpha receptor blocker capable of inhibiting glandular hyperplasia and sphincter spasm, is often used in the treatment of chronic prostatitis.9 Alternatively, tamsulosin hydrochloride, as a selective adrenoceptor blocker, can also relieve urethral resistance and urethral spasm, improving odynuria symptoms and frequency of micturition.10 This study indicated that a combination of tamsulosin hydrochloride and terazosin was more effective than terazosin treatment alone. Combination therapy also resulted in lower QLS, USS, PS and NIH-CPSI scores, indicating reduced symptoms and pain. These results indicate that this novel treatment strategy could bring therapeutic benefits in terms of both treatment efficacy and patient quality of life.

The etiology of chronic prostatitis Type-III b is complicated. The condition’s main symptoms include pelvic floor striated muscle spasms, causing large numbers of microstones, inflammation, and prostatic duct dilation. The bladder neck and posterior urinary tract contain large numbers of adrenergic receptors, resulting in spasm upon stimulation. This phenomenon may occur with lower urinary tract obstruction and impacts urodynamics.11

Previous studies have shown that inflammatory cytokines play an important role in chronic prostatitis pathogenesis.12 IL-2 is a regulatory growth factor that contributes to increased PGE-2 levels upon prostatitis, leading to microvasculature dilation, increased vascular permeability, and tissue edema.13 MIP-2 and MIP-1α are chemotactic agents that recruit macrophages, lymphocytes and neutrophils to inflammatory sites.14 Previous studies have shown that patients with chronic prostatitis have higher concentrations of MIP-2 and MIP-1α in their prostatic fluid, and that the levels of these cytokines are positively correlated with the severity of chronic prostatitis.15 This study noted that combination therapy with tamsulosin hydrochloride and terazosin decreased IL-2, PGE-2, MIP-1α, and MIP-2 levels. This indicates that this therapeutic approach inhibited patient inflammatory responses.

| Group          | n  | Time        | Lecithin body/HP | WBC/HP  |
|----------------|----|-------------|------------------|---------|
| Control Group  | 90 | Before treatment | 8.72±2.04       | 22.08±2.06 |
|                |    | After treatment | 20.74±4.21 a     | 12.89±1.93 a |
| Observation Group | 90 | Before treatment | 8.59±1.93       | 21.94±1.73  |
|                |    | After treatment | 26.83±3.94 ab    | 6.14±1.38 ab |

Data were expressed as mean ± SD; a: P < 0.05 compared against before treatment, b: P < 0.05 compared against control group; P< 0.05 indicated statistical significance.

Table-VI: Patient Adverse Reactions.

| Group          | n  | Hypotension | Dizziness and headache | Nausea | Incidence Rate |
|----------------|----|-------------|------------------------|--------|----------------|
| Control Group  | 90 | 3           | 2                      | 3      | 8.89           |
| Observation Group | 90 | 4           | 2                      | 2      | 8.89           |

Data were expressed as mean ± SD; t-test was used for between-groups analysis. Chi-square test (χ²) was used when data were expressed as percentages. P< 0.05 indicated statistical significance.
The presence of WBCs in the peripheral blood, as well as lecithin corporules in the prostatic fluid, are signs of chronic prostatitis. Moreover, the abundance of these elements is also linked to the severity of chronic prostatitis. This study showed that the combination of tamsulosin hydrochloride and terazosin can effectively reduce the number of WBC in patients’ plasma and increase the number of lecithin bodies in patients’ EPS, which fully shows that the combination therapy can significantly improve the symptoms of patients.

However, due to the complexity of chronic prostatitis pathogenesis, this study has not fully elucidated the mechanisms by which tamsulosin hydrochloride sustained-release tablets combined with terazoles acts on chronic prostatitis. The underlying genetic and molecular mechanisms need to be investigated in the future.

CONCLUSION

The application of tamsulosin hydrochloride and terazosin in the treatment of chronic prostatitis Type-III b patients has significant effect, can significantly improve the NIH-CPSI score of patients, and can reduce the MIP-2, MIP-1 in EPS α and pge-2 level, increase the number of WBS in plasma, reduce the number of nuclein bodies in EPS, and the adverse reaction rate was not significantly increased, which has a certain clinical value.

Competing interests: None.

Founding: None.

REFERENCES

1. Wu Y, Jiang H, Tan M, Lu X. Screening for chronic prostatitis pathogens using high-throughput next-generation sequencing. Prostate. 2020;80(7):577-587. doi: 10.1002/pros.23971
2. Motrich RD, Breser ML, Molina RI, Tissera A, Olmedo JJ, Rivero VE. Patients with chronic prostatitis/chronic pelvic pain syndrome show T helper type 1 (Th1) and Th17 self-reactive immune responses specific to prostate and seminal antigens and diminished semen quality. BJU Int. 2020;126(3):379-387. doi: 10.1111/bju.15117
3. Amano T, Fujii N, Kenny GP, Inoue Y, Kondo N. Does α1-adrenergic receptor blockade modulate sweating during incremental exercise in young endurance-trained men? Eur J Appl Physiol. 2020;120(5):1123-1129. doi: 10.1007/s00421-020-04351-3
4. Noor MA, Biyabani SR, Burney IA, Talati J. Symptomatic granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy for bladder cancer. J Pak Med Assoc. 2022;52(12):578-580.
5. Franco JVA, Turk T, Jung JH, Xiao Y-T, Iakhno S, Tirapeguy FI, et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: A Cochrane systematic review. BJU Int. 2020;125(4):490-496. doi: 10.1111/bju.14988
6. Wang J-S, Yang J, Deng S, Yu X-D, Bao B-H, Liu R-J, et al. Acupuncture combined with tamsulosin hydrochloride sustained-release capsule in the treatment of chronic prostatitis/chronic pelvic pain syndrome: A study protocol for a randomized controlled trial. Medicine (Baltimore). 2020;99(12):e19540. doi: 10.1097/MD.0000000000019540
7. Evans WJ. Diagnostic criteria for the diagnosis of type 2 diabetes: Discordance of multiple measures. Clin Endocrinol (Oxf). 2019;91(6):716-717. doi: 10.1111/cen.14100
8. Culha MG, Tuken M, Gonulats S, Cakir O, Serefgolu EC. Frequency of etiological factors among patients with acquired premature ejaculation: prospective, observational, single-center study. Int J Impot Res. 2020;32(3):352-357. doi: 10.1038/s41443-019-0188-x
9. Dolmans LS, Lebedeva ER, Velupponnar D, van Dijk EJ, Nederkoorn PJ, Hoes AW, et al. Diagnostic Accuracy of the Explicit Diagnostic Criteria for Transient Ischemic Attack: A Validation Study. Stroke. 2019;50(8):2080-2085. doi: 10.1161/STROKEAHA.119.025626
10. Kawa S, Kamisawa T, Notohara K, Fujinaga Y, Inoue D, Koyama T, et al. Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2018: Revision of Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2011. Pancreas. 2020;49(1):e13-e14. doi: 10.1097/MPA.0000000000001443
11. Lin YL, Liou HH, Wang CH, Lai YH, Kuo CH, Chen SY, et al. Impact of sarcopenia and its diagnostic criteria on hospitalization and mortality in chronic hemodialysis patients: A 3-year longitudinal study. J Formos Med Assoc. 2020;119(7):1219-1229. doi: 10.1016/j.jfma.2019.10.020
12. Zhang LG, Chen J, Meng JL, Zhang Y, Liu Y, Zhan CS, et al. Effect of alcohol on chronic pelvic pain and prostatic inflammation in a mouse model of experimental autoimmune prostatitis. Prostate. 2019;79(12):1439-1449. doi: 10.1002/pros.23866
13. Xue Y, Duan Y, Gong X, Zheng W, Li Y. Traditional Chinese medicine on treating chronic prostatitis/chronic pelvic pain syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(26):e16136. doi: 10.1097/MD.0000000000016136
14. Chen L, Bian Z, Chen J, Meng J, Zhang M, Liang C. Immunological alterations in patients with chronic prostatitis/chronic pelvic pain syndrome and experimental autoimmune prostatitis model: A systematic review and meta-analysis. Cytokine. 2021;141:155440. doi: 10.1016/j.cyto.2021.155440
15. Incrocci R, McAloon J, Montesano M, Bardahl J, Vagvala S, Stone A, et al. Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-kB in B-cell lymphomas to increase MIP-1α production. J Med Virol. 2019;91(5):845-855. doi: 10.1002/jmv.25381
16. Pericart S, Syrykh C, Amara N, Franchet C, Malavaud B, Gaulard P, et al. Exclusive B-cell phenotype of primary autoimmune pancreatitis: a potential role of chronic prostatitis. Histopathology. 2020;76(5):767-773. doi: 10.1111/his.14045

Authors’ Contributions: BD conceived and designed the study. BD and XW collected the data and performed the analysis. BD was involved in the writing of the manuscript and is responsible for the integrity of the study. XW edited the manuscript and made significant contribution to the study at different stages. All authors have read and approved the final manuscript.